No Data
Jinkai Shengke: Report for the third quarter of 2024
Genecast Biotechnology (301509.SZ): The company's products do not involve starch or other fillers and excipients.
Golden Triumph October 23rd | Jin Kaiseng Science (301509.SZ) stated on the investor interaction platform that the company provides small molecule CDMO services, and the company's products do not involve starch and other fillers and excipients.
Jinkai Life Sciences (301509.SZ): focusing on developing European and Asia-Pacific customer base.
Geelong September 11th | Jinkai Life Sciences (301509.SZ) stated at the investor relations event that the company has been actively adjusting and has taken various key measures, including: 1. Strengthening the BD team, fully leveraging the international BD team and customer cni resource index advantages, focusing on developing customers in Europe and Asia-Pacific countries, actively expanding business incrementally on the basis of striving for existing customer project orders; 2. Fully leveraging the strategic support role of the USA GMP production base and R&D center, while hedging risks, quickly achieving performance contribution from the base and introducing more projects; 3. Fully leveraging the pharmaceutical CDMO field.
Kingchem: Half-year report for the year 2024.
Kingchem: Summary of Half-Year Report in 2024.
Jinkai Shengke (301509.SZ): The net income in the first half of the year was 32.0917 million yuan, a decrease of 71.32% year-on-year.
Jinkai Shengke (301509.SZ) released its semi-annual report for 2024, with revenue of 0.262 billion yuan, a year-on-year decrease of 39.36%; net income attributable to shareholders of the listed company was 32.0917 million yuan, a year-on-year decrease of 71.32%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 24.5025 million yuan, a year-on-year decrease of 78.03%; basic earnings per share was 0.27 yuan.
No Data
No Data